PTC Therapeutics (PTCT) Misses Q4 EPS by 6c
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Join SI Premium – FREE
PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($0.85), $0.06 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $213 million versus the consensus estimate of $213.45 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Grocery Outlet Holding (GO) PT Raised to $11.50 at UBS
- Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
